Effect of deracoxib, a new COX-2 inhibitor, on the prevention of lameness induced by chemical synovitis in dogs.
Twenty-four healthy, mixed-breed hound-type dogs were evenly and randomly assigned to a placebo control group, one of four dosages of deracoxib (0.3, 1, 3, or 10 mg/kg), or carprofen (2.2 mg/kg). Oral dosing of placebo, carprofen, or deracoxib was done 30 minutes before intraarticular injection of urate crystal suspension for induction of synovitis. Ground reaction forces, subjective clinical lameness scores, pain, joint effusion, and quantitative pain threshold responses were measured in a blinded fashion before induction of synovitis and 2, 4, 6, 8, 12, and 24 hours after injection. The medium and high dosages of deracoxib were effective in preventing lameness and pain associated with synovitis. Carprofen was also somewhat effective in attenuating the severity of urate-induced synovitis but to a lesser degree than the medium dose of deracoxib. Preemptive deracoxib treatment at dosages as low as 1 mg/kg reduced lameness and pain of synovitis associated with intraarticular administration of urate crystals.
Millis
Darryl L
DL
Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, TN 37996, USA.
Weigel
Joseph P
JP
Moyers
Tamberlyn
T
Buonomo
Frances C
FC
D000284:Administration, Oral; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use*; D002227:Carbazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D016861:Cyclooxygenase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D004283:Dog Diseases / Q000473:pathology / Q000517:prevention & control*; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D005260:Female; D006614:Hindlimb; D007794:Lameness, Animal / Q000473:pathology; D008297:Male; D010146:Pain / Q000517:prevention & control / Q000662:veterinary*; D010147:Pain Measurement / Q000662:veterinary; D011446:Prospective Studies; D012720:Severity of Illness Index; D016037:Single-Blind Method; D013449:Sulfonamides / Q000008:administration & dosage / Q000627:therapeutic use*; D013585:Synovitis / Q000139:chemically induced / Q000517:prevention & control / Q000662:veterinary*; D016896:Treatment Outcome; D014527:Uric Acid; D000096926:Benzenesulfonamides
D000894:Anti-Inflammatory Agents, Non-Steroidal; D002227:Carbazoles; D016861:Cyclooxygenase Inhibitors; D013449:Sulfonamides; D014527:Uric Acid; C007005:carprofen; C471996:deracoxib; D000096926:Benzenesulfonamides